These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16006349)

  • 41. ["The amphetamine treatment helped my child". Is it time to reevaluate Swedish practice in hyperactivity syndrome?].
    Lakartidningen; 1996 Nov; 93(47):4307-8. PubMed ID: 8984302
    [No Abstract]   [Full Text] [Related]  

  • 42. Need for bedtime dose of ritalin.
    Rogers WB
    Pediatrics; 1996 Aug; 98(2 Pt 1):314. PubMed ID: 8692642
    [No Abstract]   [Full Text] [Related]  

  • 43. No news is bad news?
    J Psychosoc Nurs Ment Health Serv; 1999 Apr; 37(4):15. PubMed ID: 10218185
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
    Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
    Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment with central nervous system stimulants. Practical guidelines].
    Hvolby A; Jørgensen JI
    Ugeskr Laeger; 2004 Jan; 166(3):144-8. PubMed ID: 14870640
    [No Abstract]   [Full Text] [Related]  

  • 46. [Methylphenidate. A possibility for rare hyperactive children].
    Rev Infirm; 2004 Sep; (103):39-40. PubMed ID: 15517803
    [No Abstract]   [Full Text] [Related]  

  • 47. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH; Donnelly C
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract]   [Full Text] [Related]  

  • 49. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.
    Fernández-Jaén A; Fernández-Mayoralas DM; Pardos A; Calleja-Pérez B; Muñoz Jareño N
    Adv Ther; 2009 Dec; 26(12):1097-110. PubMed ID: 20082241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.
    Secnik K; Matza LS; Cottrell S; Edgell E; Tilden D; Mannix S
    Med Decis Making; 2005; 25(1):56-70. PubMed ID: 15673582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 53. Commentary on Singh: Not robots: children's perspectives on authenticity, moral agency and stimulant drug treatments.
    Rose S
    J Med Ethics; 2013 Jun; 39(6):371; discussion 372-3. PubMed ID: 23143998
    [No Abstract]   [Full Text] [Related]  

  • 54. Welcome to ordinary? Marketing better boys.
    Hall AL
    Am J Bioeth; 2005; 5(3):59-60; discussion W10-2. PubMed ID: 16006372
    [No Abstract]   [Full Text] [Related]  

  • 55. Ethical considerations in the use of subliminal stimulation to improve handwashing compliance: scientific utility versus autonomy of the individual.
    Edmond MB; Wenzel RP
    Infect Control Hosp Epidemiol; 1993 Feb; 14(2):107-9. PubMed ID: 8440878
    [No Abstract]   [Full Text] [Related]  

  • 56. Addiction, autonomy and ego-depletion: a response to Bennett Foddy and Julian Savulescu.
    Levy N
    Bioethics; 2006 Feb; 20(1):16-20. PubMed ID: 16680878
    [No Abstract]   [Full Text] [Related]  

  • 57. Behavior control: from the brain to the mind.
    Gaylin W
    Hastings Cent Rep; 2009; 39(3):13-6. PubMed ID: 19537615
    [No Abstract]   [Full Text] [Related]  

  • 58. Insight and the no-self in deep brain stimulation.
    Specker Sullivan L
    Bioethics; 2019 May; 33(4):487-494. PubMed ID: 30474139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deep Brain Stimulation, Authenticity and Value.
    Nyholm S; O'Neill E
    Camb Q Healthc Ethics; 2017 Oct; 26(4):658-670. PubMed ID: 28937344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing Enhancement Technologies: Authenticity as a Social Virtue and Experiment.
    Iftode C
    New Bioeth; 2019 Mar; 25(1):24-38. PubMed ID: 30650047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.